Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
22 January 2020 | Story Amanda Tongha | Photo Charl Devenish
UFS First year welcoming
New Kovsies got to experience the Kovsie feeling during the welcoming ceremony on 18 January.
Photo Gallery

‘Our bundles of joy, midwives of a better future, and the ones who carry the hope of families, communities, and villages.’ These were some of the words used to describe new first-year students starting their study journey on the Bloemfontein Campus of the University of the Free State (UFS). 

As part of the almost 8 000 students who will enrol on the three UFS campuses this year, the Bloemfontein cohort gathered on the Red Square in front of the Main Building for an official welcome at the UFS. They were addressed by Prof Francis Petersen, Rector and Vice-Chancellor, and Katleho Lechoo, President of the Bloemfontein Student Representative Council (SRC).  Despite a downpour on the day of the welcoming (17 January 2020), students and parents flocked to the venue to hear what the UFS is all about. 

Thank you for choosing the UFS 

“Do not take light the fact that you were chosen from more than 71 000 applicants,” Katleho told the class of 2020.  “An incomparable experience awaits you, and we will be there every step of the way,” he welcomed students. The SRC President urged students to grasp opportunities and to participate in student life activities. 

“Remember how fortunate you are. Only a few people who passed got accepted.” 

Prof Petersen shared a similar message, thanking first-year students for choosing the UFS. 

“The world you will be entering, now and when you graduate with your qualification, is a world that is complex, it is a world that is uncertain, it’s a world that is ambiguous, and it is a world you will have to navigate with the specific skills that you have acquired at the UFS.” 

Highlighting the achievements of Kovsie students in the fields of sports, academics, arts and culture, he encouraged students to take advantage of opportunities and skills gained during their time at the university. 

Safety a top priority

Prof Petersen also assured students that safety, both on and off campus, remains a top priority for the university. 

“At the UFS, we have zero tolerance for any violence, whether it is physical violence, gender-based violence or any form of discrimination. We are not tolerating that at all. We have developed systems, processes, and mechanisms to assist you in being safe.” 

Among those in attendance was Bianca Shaw, who travelled from Midlands, KwaZulu-Natal, to become a Kovsie. The LLB student said enrolling at the UFS, which is located in the judicial capital of South Africa, is the best for what she wants to study. “I heard from other students that I would be making the best decision. Also, the town area is safe and clean, and I am glad to be here.”

Her friend and fellow LLB student, Janѐ Bezuidenhout, said it was a difficult decision moving from Cape Town to Bloemfontein, but she felt welcome in Kovsieland. “I had the option to choose between Stellenbosch University and North-West University, but I chose the UFS as I wanted to interact with people from other cultures.” 

For Ayesha Ndlovu, the decision to move from Johannesburg to Bloemfontein came with much more freedom. The Bachelor of Divinity (Theology) student says she wants to grow away from family, learning how to be independent and just having fun. “It is a nice change of scenery compared to Johannesburg.” 

• The UFS received 71 346 applications from prospective students for admission in 2020, with 7 982 available space on the three campuses.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept